The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS.
Hyerim HaJin Hyoung KangDo Yeun KimSeung Jin BaeHee Yeon LeePublished in: BMC health services research (2022)
ASCO VF and ESMO-MCBS were applied to evaluate the newly emerging drugs in RCC and assessed their value. In-depth discussion by experts in various fields is required for appropriate clinical application in a real-world setting.